571 related articles for article (PubMed ID: 25541152)
1. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.
Musilova K; Mraz M
Leukemia; 2015 May; 29(5):1004-17. PubMed ID: 25541152
[TBL] [Abstract][Full Text] [Related]
2. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
Cerna K; Oppelt J; Chochola V; Musilova K; Seda V; Pavlasova G; Radova L; Arigoni M; Calogero RA; Benes V; Trbusek M; Brychtova Y; Doubek M; Mayer J; Pospisilova S; Mraz M
Leukemia; 2019 Feb; 33(2):403-414. PubMed ID: 30111844
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas.
Jeong D; Kim J; Nam J; Sun H; Lee YH; Lee TJ; Aguiar RC; Kim SW
Leukemia; 2015 Sep; 29(9):1868-74. PubMed ID: 25915824
[TBL] [Abstract][Full Text] [Related]
6. Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.
Yamagishi M; Katano H; Hishima T; Shimoyama T; Ota Y; Nakano K; Ishida T; Okada S; Watanabe T
Sci Rep; 2015 Dec; 5():17868. PubMed ID: 26639163
[TBL] [Abstract][Full Text] [Related]
7. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
8. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
[TBL] [Abstract][Full Text] [Related]
9. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
[TBL] [Abstract][Full Text] [Related]
10. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
[TBL] [Abstract][Full Text] [Related]
11. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
Zhu DX; Zhu W; Fang C; Fan L; Zou ZJ; Wang YH; Liu P; Hong M; Miao KR; Liu P; Xu W; Li JY
Carcinogenesis; 2012 Jul; 33(7):1294-301. PubMed ID: 22610076
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia.
Mraz M; Kipps TJ
Leuk Lymphoma; 2013 Aug; 54(8):1836-9. PubMed ID: 23597135
[TBL] [Abstract][Full Text] [Related]
14. New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.
Devan J; Janikova A; Mraz M
Semin Oncol; 2018 Oct; 45(5-6):291-302. PubMed ID: 30360879
[TBL] [Abstract][Full Text] [Related]
15. Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.
Akhter A; Street L; Ghosh S; Burns BF; Elyamany G; Shabani-Rad MT; Stewart DA; Mansoor A
Hematol Oncol; 2017 Mar; 35(1):79-86. PubMed ID: 26354285
[TBL] [Abstract][Full Text] [Related]
16.
Musilova K; Devan J; Cerna K; Seda V; Pavlasova G; Sharma S; Oppelt J; Pytlik R; Prochazka V; Prouzova Z; Trbusek M; Zlamalikova L; Liskova K; Kruzova L; Jarosova M; Mareckova A; Kornauth C; Simonitsch-Klupp I; Schiefer AI; Merkel O; Mocikova H; Burda P; Machova Polakova K; Kren L; Mayer J; Zent CS; Trneny M; Evans AG; Janikova A; Mraz M
Blood; 2018 Nov; 132(22):2389-2400. PubMed ID: 30213873
[TBL] [Abstract][Full Text] [Related]
17. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
Rao E; Jiang C; Ji M; Huang X; Iqbal J; Lenz G; Wright G; Staudt LM; Zhao Y; McKeithan TW; Chan WC; Fu K
Leukemia; 2012 May; 26(5):1064-72. PubMed ID: 22116552
[TBL] [Abstract][Full Text] [Related]
18. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
19. miR-138-1* regulates aflatoxin B1-induced malignant transformation of BEAS-2B cells by targeting PDK1.
Wang Y; Zhang Z; Wang H; Zhang Y; Ji M; Xu H; Wang C; Sun Z; Gao W; Wang SL
Arch Toxicol; 2016 May; 90(5):1239-49. PubMed ID: 26084420
[TBL] [Abstract][Full Text] [Related]
20. Genetic landscape and deregulated pathways in B-cell lymphoid malignancies.
Rosenquist R; Beà S; Du MQ; Nadel B; Pan-Hammarström Q
J Intern Med; 2017 Nov; 282(5):371-394. PubMed ID: 28631441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
